Výsledky vyhledávání - "STEPHEN BARDOT"

Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy

Autor: Jay T. Bishoff, Daniel J. Canter, Stephen J. Freedland, Todd Cohen, Margaret Variano, Thorsten Schlomm, Maria Latsis, Jonathan D. Tward, Steven Stone, Saradha Rajamani, Shams Halat, Stephen Bardot

Publikováno v: Prostate Cancer and Prostatic Diseases

Background Accurate risk stratification can help guide appropriate treatment decisions in men with localized prostate cancer. Here, we evaluated the independent ability of the molecular cell cycle progression (CCP) score and the combined cell-cycle c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b93e84de384b6d161e3b1cb3bf149b40
http://europepmc.org/articles/PMC7027968

Zobrazit plný text záznamu

Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer

Autor: Daniel Canter, Julia Reid, Stephen Bardot, Zaina Sangale, Saradha Rajamani, Kristen E. Gurtner, Margaret Variano, Michael K. Brawer, Steven Stone, Maria Latsis, Shams Halat

Publikováno v: European Urology. 75:515-522

Better prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain.To evaluate the utility of both a cell cycle progression (CCP) score and a cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e79ca28849951888b0a3d4e0ce156165
https://doi.org/10.1016/j.eururo.2018.10.028

Zobrazit plný text záznamu

Effect of the Need for Preoperative Dialysis on Perioperative Outcomes on Patients Undergoing Laparoscopic Nephrectomy: An Analysis of the National Surgical Quality Improvement Program Database

Autor: Marc R. Matrana, Daniel J. Canter, Kathleen Lata-Arias, Stephen Bardot, Danica May, Dunia T. Khaled

Publikováno v: Urology. 124:154-159

Objective: To investigate whether patients requiring dialysis are a higher risk surgical population and would experience more perioperative adverse events even when undergoing a perceived less invasive operation as a laparoscopic radical nephrectomy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cadd6752020df6913c9deede6e48228d
https://doi.org/10.1016/j.urology.2018.11.010

Zobrazit plný text záznamu

Abstract 3104: Inverse correlation of circulating CD8+ T cells with tumor burden from immune checkpoint treatment in humanized orthotopic model of renal cell carcinoma

Autor: Xin Zhang, Amita Bhattarai, Ravan Moret, Grace Maresh, Alicia Nicole Ray, David Woods, Rachel Graham, Maria Latis, Stephen Bardot, Li Li

Publikováno v: Cancer Research. 82:3104-3104

Background: Renal cell carcinoma (RCC) is a highly heterogeneous and metastatic disease with a widely varying prognosis. RCC is the first solid tumor treated with immune checkpoint blockade and approved by the FDA for showing improvement of clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0897f7d1a9cdbdf1db72a8fc3464d9a5
https://doi.org/10.1158/1538-7445.am2022-3104

Zobrazit plný text záznamu

Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy

Autor: Jay T. Bishoff, Stephen J. Freedland, Michael K. Brawer, Darl D. Flake, Lauren Lenz, Stephen Bardot, Thorsten Schlomm, Jonathan D. Tward, Troy Scroggins, Todd Cohen, Daniel J. Canter, Steven Stone

Publikováno v: Clinical genitourinary cancer. 19(4)

Introduction The combined clinical cell-cycle risk (CCR) score is a validated model that combines the cell-cycle progression (CCP) score with the University of California San Francisco Cancer of the Prostate Risk Assessment (CAPRA) score. This score

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65becdf2789078a80bbfc97b8f29e478
https://pubmed.ncbi.nlm.nih.gov/33608228

Zobrazit plný text záznamu

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma

Autor: Shruthi Naik, Bradley C. Leibovich, Tanner Miest, Stephen Bardot, Paul R Young, Stephen A. Boorjian, Mark L. Gonzalgo, Loren Herrera Hernandez, Matthew K. Tollefson, Jeffrey Karnes, Paige Nichols, Tessa Kroeninger, Rachel Graham, Monica Reckner, Alysha Newsom, Nandakumar Packiriswamy, Kah Whye Peng, Erol Wiegert, Alice Susannah Bexon

Publikováno v: Journal of Clinical Oncology. 40:509-509

509 Background: Bladder cancer is a leading cause of cancer death in the United States. The histology in > 90% of cases is urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc9cdf9383f47f9bfbcdab70bf8c0425
https://doi.org/10.1200/jco.2022.40.6_suppl.509

Zobrazit plný text záznamu

A patient-derived orthotopic xenograft model enabling human high-grade urothelial cell carcinoma of the bladder tumor implantation, growth, angiogenesis, and metastasis

Autor: Eric Laborde, Shams Halat, Michael P. Marino, Li Li, Xin Zhang, Linh Hellmers, Maria Latsis, M'Liss A. Hudson, Daniel Canter, Ravan Moret, Marc R. Matrana, Jessie Gills, Sunil Talwar, Grace Maresh, Maureen Shuh, John Nelson, Jakob Reiser, Stephen Bardot

Publikováno v: Oncotarget

// Jessie Gills 1, * , Ravan Moret 2, * , Xin Zhang 2 , John Nelson 1 , Grace Maresh 2 , Linh Hellmers 2 , Daniel Canter 1 , M’Liss Hudson 1, 6 , Shams Halat 3 , Marc Matrana 4 , Michael P. Marino 5 , Jakob Reiser 5 , Maureen Shuh 2 , Eric Laborde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7e6816b0d6fddf7facda219d5fe6ba
http://europepmc.org/articles/PMC6135689

Zobrazit plný text záznamu

Abstract P190: Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma

Publikováno v: Molecular Cancer Therapeutics. 20:P190-P190

Background: Bladder cancer is a leading cause of cancer death in the United States1. The histology in > 90% of cases is urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current sta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b180ee67dcaf5598c9ae21be2041999
https://doi.org/10.1158/1535-7163.targ-21-p190

Zobrazit plný text záznamu

422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundBladder cancer is a leading cause of cancer death in the United States.1 The histology in > 90% of cases is urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current stand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28e5063301836d9fce5b4b4dc6df94a
https://doi.org/10.1136/jitc-2021-sitc2021.422

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání